Rocky Hill-based medical technology firm Lumeda, which is developing a lung cancer-killing light therapy system, raised $4.3 million through its Series A funding round and now expects to start human clinical studies by the middle of this year, company officials announced Thursday.
Combined with a seed funding round that took place early last year, Lumeda has raised $5.3 million to date, they said.
The Series A round was led by Connecticut Innovations, the state’s venture investment arm, with participation from Cycle Venture Partners, a Branford-based venture capital group.
The company expects two first-in-human clinical studies to commence at Roswell Park Comprehensive Cancer Center in Buffalo, New York, by mid-2021, and CEO Sandy Zinke said the plan is to “expand testing to other sites in the U.S., Europe and Japan.”
Lumeda Announces Closing of $4.3M Series A Financing with Clinical Studies Due to Commence in 2021
Share Article
Funding to advance product design and clinical testing as company strives to improve outcomes for lung cancer patients ROCKY HILL, Conn. (PRWEB) April 08, 2021
Lumeda Inc., a medical technology company advancing Photodynamic Therapy (PDT) as an intraoperative adjuvant treatment for patients during lung cancer surgery, today announced the closing of its Series A financing. The round was led by Connecticut Innovations, with participation from Cycle Venture Partners and brings the total amount raised to date to $5.3M. Both firms, along with angel investors, participated in the company’s Seed funding round in early 2020. The new capital will be used to further develop Lumeda’s breakthrough PDT system, which leverages artificial intelligence (AI) and proprietary software and hardware to enable controlle
Medicine is moving into the selfie age, with the increased use of tiny cameras probing the insides of a body. The idea has become especially useful in the COVID-19 era.
People of a certain age are familiar with colonoscopies, a tiny camera at the end of a wire that probes your lower insides and can help a doctor remove polyps seen on a screen at the other end of the device. It s part of the search for colorectal cancers, the second-most deadly cancer.
Now, the increasing idea of looking at your insides by swallowing a tiny camera is allowing physicians to view your entire digestive system.
E-Mail
BUFFALO, N.Y. - The University at Buffalo has received a $1.5 million grant from the United States Department of Defense to develop new therapies that help reduce chronic inflammation and immunosuppression in oral cancers.
Through the three-year grant, the research will center on a type of white blood cell called a macrophage that - after migrating to oral tumors - triggers uncontrolled inflammation, which suppresses the body s immune response and lowers the effectiveness of anticancer therapies.
The researchers aim to reprogram the macrophages by targeting genes that regulate inflammation. By lowering inflammation, oral cancers will become more sensitive to new and traditional chemotherapies.
New Director Sets Aggressive Goals for Cancer Center insideindianabusiness.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insideindianabusiness.com Daily Mail and Mail on Sunday newspapers.